.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Poster session

Poster session 13

Appointment

Date: 09 Dec

Time: 15:30 – 17:00

Location / Stream:

ePoster Terminal 3

Chair

Programme

15:30 – 15:35 3 Min. 2 Min.
ePoster
P137a
Long-Term Treatment With Lasmiditan in Patients With Migraine: Results From the Open-Label Extension of the CENTURION Study
Saygin Gonderten (Dubai/ AE)
Migraine
15:35 – 15:40 3 Min. 2 Min.
ePoster
P138
Patterns of use of monoclonal antibodies for the preventive treatment of migraine: Results from the OVERCOME (EU) study
Saygin Gonderten (Dubai/ AE)
Stefan Evers (Münster/ DE)
Migraine
15:40 – 15:45 3 Min. 2 Min.
ePoster
P139
Cardiovascular risk factors and migraine: Results from the population-based Rotterdam study
Linda Al-Hassany (Rotterdam/ NL)
Epidemiology, Migraine
15:45 – 15:50 3 Min. 2 Min.
ePoster
P141
Safety and tolerability of atogepant: a post hoc analysis of pooled data from four clinical trials
Krisztian Nagy (Budapest/ HU)
Migraine
15:50 – 15:55 3 Min. 2 Min.
ePoster
P142
Effect of atogepant on Migraine-Specific Quality of Life Questionnaire and Headache Impact Test-6 in a 12-week, double-blind, randomized, phase 3 (PROGRESS) trial for preventive treatment of chronic migraine (CM)
Krisztian Nagy (Budapest/ HU)
Migraine
15:55 – 16:00 3 Min. 2 Min.
ePoster
P143
Effect of atogepant on the Activity Impairment in Migraine–Diary and Work Productivity and Activity Impairment Questionnaire in a 12-week, double-blind, randomized, phase 3 (PROGRESS) trial for preventive treatment of chronic migraine (CM)
Richard B. Lipton (Bronx, NY/ US)
Migraine
16:00 – 16:05 3 Min. 2 Min.
ePoster
P144
Erenumab as a first line preventive treatment for episodic migraine in Spain: a cost-effectiveness analysis.
Pablo Irimia (Pamplona/ ES)
Migraine
16:05 – 16:10 3 Min. 2 Min.
ePoster
P145
Impact of migraine attack accompanying symptoms in treatment response to anti-CGRP monoclonal antibodies treatment and their evolution after 6 months
Alicia Alpuente (Barcelona/ ES)
CGRP inhibitors in the clinic, Migraine
16:10 – 16:15 3 Min. 2 Min.
ePoster
P146
Mapping Migraine Minds: A cross-sectional survey to compare the difference in the level of treatment expectations and satisfaction for migraine among Indian male & female patients
Sneha Thakur (Mumbai/ IN)
Epidemiology, Migraine
16:15 – 16:20 3 Min. 2 Min.
ePoster
P147
Migraine, chronic neck pain and endurance muscle cervical test – a controlled study
Amanda Rodrigues (Ribeirão Preto/ BR)
Migraine, Multidisciplinary clinical assessments
16:20 – 16:25 3 Min. 2 Min.
ePoster
P150
Onabotulinum toxinA for unremitting chronic migraine: assessment of muscle function and strength, efficacy and safety after 10 years of continuous treatment.
Guy Pierre Boudreau (Montreal/ CA)
Migraine
16:25 – 16:30 3 Min. 2 Min.
ePoster
P151
Long-term Effectiveness and Safety of Erenumab in patients with Migraine: a Systematic Review and Single-Arm Meta-analysis
Fernanda Ferreira Bomtempo (Belo Horizonte/ BR)
CGRP inhibitors in the clinic, Migraine
16:30 – 16:35 3 Min. 2 Min.
ePoster
P152
Prospective evaluation of migraine premonitory symptoms during the 30 days period
Kirill Skorobogatykh (Moscow/ RU)
Data science in research and digital medicine, Migraine
16:35 – 16:40 3 Min. 2 Min.
ePoster
P153
Prevalence of sinonasal symptoms in migraine without aura (results from Migraine in Poland - a nationwide cross-sectional survey)
Marcin Straburzyński (Olsztyn/ PL)
Migraine
16:40 – 16:45 3 Min. 2 Min.
ePoster
P149
Safety and Tolerability of Rimegepant Every Other Day for Preventive Treatment of Migraine Plus As-Needed for Acute Treatment of Migraine: Results from A 52-Week, Open-Label Extension Study
Robert Croop (New Haven/ US)
CGRP inhibitors in the clinic, Migraine
16:45 – 16:50 3 Min. 2 Min.
ePoster
P148
Effects of Rimegepant 75 mg on Monthly Migraine Days: a 52-Week, Open-Label Extension Study
Jessica Ailani
CGRP inhibitors in the clinic, Migraine
16:50 – 16:55 3 Min. 2 Min.
ePoster
P136a
Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial
Robert Croop (New Haven/ US)
CGRP inhibitors in the clinic, Migraine
16:55 – 17:00 3 Min. 2 Min.
ePoster
P140
A prospective evaluation of neurological presentations to a National Neuro-Behçet Clinic in the UK- Migraine is the commonest neurological complaint in Behçet's disease
Mona Ghadiri-Sani (Liverpool/ GB)
Migraine, Secondary headaches